Document Detail

Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
MedLine Citation:
PMID:  23252565     Owner:  NLM     Status:  In-Data-Review    
Monoclonal antibodies (mAbs) - rituximab, ofatumumab and alemtuzumab - have been approved for use in the therapy of chronic lymphocytic leukemia (CLL). Recently, a new generation of anti-CD20 mAbs has become available for preclinical studies and clinical trials. These antibodies were engineered to have augmented antitumor activity by increasing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and Fc-binding affinity for the low-affinity variants of the Fcγ receptor IIIa. The most promising mAb directed against CD20 is obinutuzumab (GA-101). mAbs directed against CD22, CD37 and CD40 have also shown some activity in CLL. In addition, small modular immunopharmaceuticals - TRU-015 (anti-CD20) and TRU-016 (anti-CD37) - that retain Fc-mediated effector functions have been developed and investigated in preclinical studies and clinical trials. Antibody-drug conjugates and recombinant immunotoxins are also being evaluated in lymphoid malignancies. Further studies will elucidate the role of these agents in the treatment of CLL.
Tadeusz Robak
Related Documents :
24931955 - Autoantibodies to the rpp25 component of the th/to complex are the most common antibodi...
23846425 - Carb-3 is the superior anti-cd15 monoclonal antibody for immunohistochemistry.
24945525 - An antibody array in a multiwell plate format for the sensitive and multiplexed detecti...
23967055 - Intracellular reprogramming of expression, glycosylation, and function of a plant-deriv...
9020315 - Anti-gal igg antibodies in sera of newborn humans and baboons and its significance in p...
23888345 - Delayed diagnosis of lyme neuroborreliosis presenting with abducens neuropathy without ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Future oncology (London, England)     Volume:  9     ISSN:  1744-8301     ISO Abbreviation:  Future Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101256629     Medline TA:  Future Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  69-91     Citation Subset:  IM    
Department of Hematology, Medical University of Lodz, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland and Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intraperitoneal delivery of nanoparticles for cancer gene therapy.
Next Document:  Triptorelin in the management of prostate cancer.